Medtronic has announced the findings of new studies showing the long-term performance benefits of its CoreValve transcatheter aortic valve replacement (TAVR) system.
The company has unveiled positive outcomes from the CoreValve US Pivotal Extreme Risk Study and the real-world NOTION trial, both of which examined patients with the CoreValve TAVR system at five years post-implant.
“Medtronic has reported new data showing the long-term effectiveness of its CoreValve transcatheter aortic valve replacement system.“
Both studies demonstrated that patients implanted with the CoreValve TAVR system showed strong haemodynamic performance and improved quality of life after five years.
Dr Pieter Kappetein, vice-president and chief medical officer of Medtronic's heart valve therapies business, said: "It's satisfying to see that many of these early patients continue to do well with the self-expanding TAVR platform, especially as the therapy expands to lower-risk patients who are expected to live longer."
The original CoreValve system was launched in 2014, followed by the release of the CoreValve Evolut R system in 2015 and the third-generation Evolut Pro TAVR system for extreme, high and intermediate-risk patients in 2017.
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices